as attached
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Eris Lifesciences Ltd reported strong FY2025-26 consolidated results with net profit after tax of Rs 647.51 Crore, a 72.8% increase from Rs 374.67 Crore in the previous year. Consolidated revenue from operations grew 8.2% to Rs 3,129.42 Crore. The Board declared an interim dividend of Rs 7.21 per equity share (721% on Re. 1 face value) for FY 2026-27, with record date May 29, 2026. Operating margin expanded to 27.11% from 24.89% year-on-year. An exceptional item of Rs 17.24 Crore was recorded due to new labour code implementation. Auditors Walker Chandiok & Co LLP issued unmodified (clean) opinions on both standalone and consolidated financials. The company completed acquisition of remaining minority shares in Swiss Parenterals Ltd, making it a wholly-owned subsidiary.
Strong PAT growth of 72.8% and margin expansion signal healthy operational performance. The generous 721% interim dividend demonstrates management confidence. However, trade receivables increased significantly (Rs 680 Crore vs Rs 459 Crore) which investors should monitor.